RYTM

Rhythm Pharmaceuticals, Inc. is a Boston-based biopharmaceutical innovator focused on developing groundbreaking therapies for rare genetic obesity disorders. The company's flagship product, Imcivree (setmelanotide), targets the underlying biological mechanisms of severe obesity associated with specific genetic conditions, providing critical treatment options for an underserved patient demographic. Leveraging its expertise in melanocortin system research, Rhythm is poised to expand its pipeline, further enhancing patient outcomes and quality of life, and reinforcing its leadership position at the intersection of genetic medicine and metabolic health.